The raised FY guidance and sustained profitability signal accelerating commercial execution. Monitor Q4 2026 for vitiligo Phase 2 data and the February 2027 PDUFA for the infant atopic dermatitis sNDA, both potential catalysts. The stock's strong momentum may continue, but the 86% bullish analyst consensus already reflects high expectations.
Drug in focus
ARQT drug pipeline →ZORYVE
▲ Bullish Named in this press release- Impact
- Phase
- Approved (commercial stage)
- Time to market
- Already approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
- Next catalyst
- PDUFA date · Feb 23, 2027 99d
What to watchThe next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $26.43entry
- T+1 · 3mo ago −4.31%α −4.92% · $25.29
- T+5 · 3mo ago −2.27%α −3.48% · $25.83
- T+20 · 3mo ago −10.48%α −11.08% · $23.66
- T+60 · 18d ago +21.34%α +23.01% · $32.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arcutis reported Q2 2026 product revenue of $129.9M (+59% YoY) and net income of $15.0M ($0.11 EPS), a significant turnaround from a net loss of -$15.9M in Q2 2025. The company raised full-year 2026 net product sales guidance from $480-495M to $525-540M, reflecting strong ZORYVE demand and improved gross-to-net pricing. Despite the EPS miss vs consensus ($0.11 actual vs $0.05 estimate, a +120% beat), the stock is likely to react positively to the revenue beat, raised guidance, and sustained positive operating cash flow of $12.6M.
Key Financial Metrics
Key Facts
- Q2 2026 product revenue of $129.9M (+59% YoY, +23% sequential)
- Net income of $15.0M ($0.11 EPS) vs net loss of -$15.9M in Q2 2025
- Raised FY2026 net product sales guidance to $525-540M from $480-495M
- Positive operating cash flow of $12.6M in Q2 2026
- FDA approved ZORYVE cream 0.3% for children with plaque psoriasis down to age 2
- FDA accepted sNDA for ZORYVE cream 0.05% in infants with atopic dermatitis (PDUFA Feb 23, 2027)
- Completed enrollment of Phase 2 vitiligo study; topline results expected Q4 2026
Financial Impact
Q2 revenue $129.9M (+59% YoY); raised FY guidance by $45M at midpoint to $532.5M; net income $15.0M vs loss of -$15.9M YoY
Risk Factors
- Competition from other topical therapies in psoriasis and atopic dermatitis
- Execution risk on sales force expansion into primary care and pediatrics
- Pipeline setbacks (vitiligo Phase 2 data, ARQ-234 Phase 1a/1b)
- Dependence on ZORYVE franchise for all revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3339629 |
Track record
34 reports on ARQT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $28.26 Now $27.15 −3.93% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
- Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers